Cappelli R., Nicora M., Di Perri T.
Drugs under experimental and clinical research, 1988
Abstract
The effectiveness and tolerability of a venotropic drug (RAES) composed of an extract of Ruscus aculeatus (16.5 mg), hesperidin (75 mg) and ascorbic acid (50 mg) were evaluated in 40 patients (30 female, 10 male) aged between 28 and 74 years, suffering from chronic phlebopathy of the lower limbs. The cross-over, double-blind trial involved two periods of treatment of 2 months with the drug (2 capsules, 3 times/day) or with placebo, and an interim period of 15 days for wash-out. An overall tendency for improvement occurred that was more distinct during the periods of treatment with the drug. In fact, symptoms and plethysmographic parameters (in particular MVIV 40 and 60) immediately changed significantly in correspondence with the administration of RAES. The biological and clinical tolerability were excellent.
| PMID: | 3048951 |
|---|---|
| Category: | Varicose Veins |
The best supplements with Ruscus Aculeatus in Varicose Veins category:
- Varicorin - Varicorin is the ideal solution for people suffering from varicose veins, spider veins or swollen legs. It contains among others: Ruscus Aculeatus.
Articles similar to "Use of extract of Ruscus aculeatus in venous disease in the lower limbs."
- The role of Ruscus Aculeatus in Varicose Veins: The place of Ruscus extract, hesperidin methyl chalcone, and vitamin C in the management of chronic venous disease. (Despite continuous improvement in our knowledge and management of chronic venous disease (CVD), certain areas, such as the role of muscarinic receptors in the pathology and treatment of CVD, remain unexplored...)
- The impact of Ruscus Aculeatus on Varicose Veins: Combination of Ruscus aculeatus extract, hesperidin methyl chalcone and ascorbic acid: a comprehensive review of their pharmacological and clinical effects and of the pathophysiology of chronic venous disease. (This paper focuses on Ruscus aculeatus extract (Ruscus extract) and its combination with hesperidin methyl chalcone (HMC) and ascorbic acid (AA), which have been safely and effectively used in CVD treatment for more than 50 years in some European countries...)